This hypothesis is supported by our study as we show that combined pharmacological targeting of Wnt and MEK is more efficient in reducing tumour growth than single agent treatment, in both CRC cells and a patient-derived cancer xenograft model. Here, MAP2K7 is linked to neoplasm.